
A part of the largest development program in the history of the Danish company ALK is coming to an end, after the company announced yesterday that the first of two pivotal phase III studies with a new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases, Mitizax, has been concluded with positive results.
The MERIT trial met its primary end-points, as the results demonstrated that the treatment has a significant clinical effect on so-called allergic rhinitis. The positive results make it possible for the company to submit an application for marketing approval to the European authorities in 2014, according to a press release.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app